The Promise of NK Engager Bispecific Antibodies (with CSO Dr. Wei Li)

Bispecific antibodies to engage Vγ9Vδ2-T cells for cancer immunotherapyПодробнее

Drawn to Science | T-cell bispecific antibodiesПодробнее

Innate cell engager (ICE®) AFM13 combined with cord blood-derived NK cells for R/R CD30+ lymphomaПодробнее

What Are the Implications of Treatment Resistance on Complex Medical Conditions?Подробнее

Understanding Bispecific AntibodiesПодробнее

Activated T cell attacks a cancer cellПодробнее

Antibody-based and bispecific T-cell dependent therapiesПодробнее

Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell LymphomaПодробнее

Harnessing the Power of NK Cells to Defeat Cancer - Cytovia TherapeuticsПодробнее

Isolation of B cells and NK CellsПодробнее

David Siegel, MD, PhD, regarding bispecific antibodies in the management of relapsed/refractory MMПодробнее

Cancer_CellПодробнее

Bispecific antibodies enable synthetic agonistic receptor T-cell therapy in melanomaПодробнее

Lecture 8 part 7: complement, inflammation, fever, NK cells, vaccines: editedПодробнее

Cancer Immunotherapy: Bispecific & Trispecific AntibodiesПодробнее

Investigation of NK cell-driven tumor immunity using novel image cytometry detection methodПодробнее

Bispecific antibodies in lymphoma: an updateПодробнее

How Does It Work? | Bispecific AntibodiesПодробнее